Role of immunotherapy in the treatment of advanced non-small-cell lung cancer

被引：8

作者：

Rijavec, Erika ^{[1
]}

Genova, Carlo ^{[1
]}

Alama, Angela ^{[1
]}

Barletta, Giulia ^{[1
]}

Sini, Claudio ^{[1
]}

Pronzato, Paolo ^{[2
]}

Coco, Simona ^{[1
]}

Dal Bello, Maria Giovanna ^{[1
]}

Savarino, Graziana ^{[1
]}

Truini, Anna ^{[1
]}

Boccardo, Francesco ^{[3
,4
]}

Grossi, Francesco ^{[1
]}

机构：

[1] Ist Nazl Ric Canc, IRCCS AOU San Martino IST, UOS Tumori Polmonari, I-16132 Genoa, Italy

[2] Ist Nazl Ric Canc, IRCCS AOU San Martino IST, UOC Oncol Med A, I-16132 Genoa, Italy

[3] Ist Nazl Ric Canc, IRCCS AOU San Martino IST, UOC Oncol Med B, I-16132 Genoa, Italy

[4] Univ Genoa, Dipartimento Med Interna & Specialita Med DIMI, Genoa, Italy

来源：

FUTURE ONCOLOGY | 2014年 / 10卷 / 01期

关键词：

advanced non-small-cell lung cancer; cancer vaccine; CTLA-4; IL-2; immunotherapy; PD-1; TLF; TLR9; LOW-DOSE INTERLEUKIN-2; RANDOMIZED PHASE-II; MHC CLASS-I; DOUBLE-BLIND; TLR9; AGONISTS; UP-REGULATION; TUMOR; PLUS; IPILIMUMAB; EXPRESSION;

D O I：

10.2217/FON.13.145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

After several decades of modest results with nonspecific immune stimulants, immunotherapy has become an exciting approach in the treatment of cancer. Although non-small-cell lung cancer has not been considered an immunogenic disease for very long, a better understanding of tumor immunology and the identification of new targets have led to the development of many clinical trials of immune-based therapies for this neoplasm. Promising results from many clinical trials suggest that immunotherapy could be an effective strategy in the management of advanced non-small-cell lung cancer. Further studies are required to help clinicians in the selection of patients who are more likely to benefit from immunotherapy strategies by the identification of biomarkers and to understand when the combination of immunotherapy with other agents should be recommended.

引用

页码：79 / 90

页数：12

共 60 条

[1]

[Anonymous], J CLIN ONCOL S

[2] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[3] Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade [J].

Breunis, Willemijn B. ;

Tarazona-Santos, Eduardo ;

Chen, Renee ;

Kiley, Maureen ;

Rosenberg, Steven A. ;

Chanock, Stephen J. .

JOURNAL OF IMMUNOTHERAPY, 2008, 31 (06) :586-590

[4]

Brunner MC, 1999, J IMMUNOL, V162, P5813

[5] Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial [J].

Butts, Charles ;

Maksymiuk, Andrew ;

Goss, Glenwood ;

Soulieres, Denis ;

Marshall, Ernie ;

Cormier, Yvon ;

Ellis, Peter M. ;

Price, Allan ;

Sawhney, Ravinder ;

Beier, Frank ;

Falk, Martin ;

Murray, Nevin .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (09) :1337-1342

[6] CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction [J].

Contardi, E ;

Palmisano, GL ;

Tazzari, PL ;

Martelli, AM ;

Falà, F ;

Fabbi, M ;

Kato, T ;

Lucarelli, E ;

Donati, D ;

Polito, L ;

Bolognesi, A ;

Ricci, F ;

Salvi, S ;

Gargaglione, V ;

Mantero, S ;

Alberghini, M ;

Ferrara, GB ;

Pistillo, MP .

INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (04) :538-550

[7] Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine [J].

Correale, Pierpaolo ;

Miano, Salvatora Tindara ;

Remondo, Cinzia ;

Migali, Cristina ;

Rotundo, Maria Saveria ;

Macri, Paolo ;

Tagliaferri, Pierosandro ;

Tassone, Pierfrancesco ;

Caraglia, Michele ;

Gotti, Giuseppe ;

Francini, Guido .

CANCER BIOLOGY & THERAPY, 2009, 8 (06) :497-502

[8] Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses [J].

De la Rosa, Gonzalo ;

Yang, De ;

Tewary, Poonam ;

Varadhachary, Atul ;

Oppenheim, Joost J. .

JOURNAL OF IMMUNOLOGY, 2008, 180 (10) :6868-6876

[9]

Declerck S, 2013, FUTURE ONCOL, DOI [10.2217/FON13.145, DOI 10.2217/FON13.145]

[10] Immunologic biomarkers as correlates of clinical response to cancer immunotherapy [J].

Disis, Mary L. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (03) :433-442

← 1 2 3 4 5 6 →